2012年5月
Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
BONE MARROW TRANSPLANTATION
- 巻
- 47
- 号
- 5
- 開始ページ
- 700
- 終了ページ
- 705
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1038/bmt.2011.158
- 出版者・発行元
- NATURE PUBLISHING GROUP
Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients with hematologic diseases (median age, 44; range, 25-67 years, seven males) who received a 1-day reduced-intensity preparative regimen given as a re-transplantation for primary graft failure. The salvage regimen consisted of fludarabine, cyclophosphamide, alemtuzumab and TBI, all administered 1 day before re-transplantation. All patients received T-cell replete PBSCs from the same or a different haploidentical donor (n = 10) or from the same matched sibling donor (n = 1). Neutrophil counts promptly increased to >500/mu L for 10 of the 11 patients at a median of 13 days. Of these, none developed grade III/IV acute GVHD. At present, 8 of the 11 patients are alive with a median follow-up of 11.2 months from re-transplantation and 5 of the 8 are in remission. In conclusion, this series suggests that our 1-day preparative regimen is feasible, leads to successful engraftment in a high proportion of patients, and is appropriate for patients requiring immediate re-transplantation after primary graft failure following reduced-intensity transplantation. Bone Marrow Transplantation (2012) 47, 700-705; doi:10.1038/bmt.2011.158; published online 1 August 2011
- リンク情報
-
- DOI
- https://doi.org/10.1038/bmt.2011.158
- J-GLOBAL
- https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502865802659601
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/21804612
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214602
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000303923500014&DestApp=WOS_CPL
- URL
- http://europepmc.org/abstract/med/21804612
- ID情報
-
- DOI : 10.1038/bmt.2011.158
- ISSN : 0268-3369
- J-Global ID : 201502865802659601
- ORCIDのPut Code : 24261763
- PubMed ID : 21804612
- PubMed Central 記事ID : PMC3214602
- Web of Science ID : WOS:000303923500014